Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680790 · ClinicalTrials.gov registry record · Phase 3
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 3
- Development phase
- 850
- Enrollment target
NCT07680790 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 850 participants.
The verdict
NCT07680790, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 850 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Osimertinib
- DRUG Pemetrexed
- DRUG Iza-bren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2026-09-30 |
| Est. Completion | 2031-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07680790
The ClinicalTrials.gov registry entry for NCT07680790 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT07680790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07680790 about?
NCT07680790 is a clinical study titled "Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)". The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
What is the current status of trial NCT07680790?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 850 participants. The study started on 2026-09-30. Estimated completion is 2031-12-30.
What interventions are being tested in trial NCT07680790?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG), Iza-bren (DRUG).
Who is sponsoring clinical trial NCT07680790?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.